Oberg et al. reported that ex-vivo expanded γδ T cell administration with the HER2/Vγ9 bispecific antibody significantly reduced the growth of pancreatic cancer and colon cancer in preclinical models [132,133]. Here, ERBB2 is linked to colonic neoplasm.